MARSHALL WACE, LLP - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 241 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.3%.

Quarter-by-quarter ownership
MARSHALL WACE, LLP ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q3 2023$2,237,162
-67.4%
42,948
-60.4%
0.01%
-61.5%
Q2 2023$6,866,926
-95.5%
108,448
-95.7%
0.01%
-95.5%
Q1 2022$154,185,000
+23.3%
2,519,764
+5.5%
0.29%
+26.4%
Q4 2021$125,003,000
+46.1%
2,388,294
+4.0%
0.23%
-34.9%
Q3 2021$85,582,000
-24.3%
2,295,634
-17.2%
0.36%
-30.7%
Q2 2021$113,125,000
+17.6%
2,771,304
-2.2%
0.51%
+16.1%
Q1 2021$96,174,000
+0.3%
2,834,460
-6.0%
0.44%
-15.2%
Q4 2020$95,900,000
+24.1%
3,015,732
+0.1%
0.52%
+5.1%
Q3 2020$77,298,000
+128.5%
3,012,377
+128.6%
0.50%
+108.9%
Q2 2020$33,831,000
+221.4%
1,317,930
+92.5%
0.24%
+125.7%
Q1 2020$10,526,000
+2662.7%
684,778
+6873.3%
0.10%
+3400.0%
Q2 2016$381,000
-69.4%
9,820
-57.6%
0.00%
-75.0%
Q4 2015$1,245,000
+66.0%
23,148
+23.5%
0.01%
+33.3%
Q3 2015$750,00018,7380.01%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q1 2022
NameSharesValueWeighting ↓
TANG CAPITAL MANAGEMENT LLC 700,000$42,833,0008.57%
SILVERARC CAPITAL MANAGEMENT, LLC 308,819$18,897,0007.82%
Vahanian & Associates Financial Planning Inc. 45,533$2,786,0006.44%
DCF Advisers, LLC 238,500$14,594,0006.39%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 50,956$20,930,0004.72%
SUVRETTA CAPITAL MANAGEMENT, LLC 1,531,923$93,738,0002.86%
Nicholas Investment Partners, LP 562,373$34,412,0002.45%
Bellevue Group AG 3,429,619$209,859,0002.44%
WASATCH ADVISORS LP 7,477,868$457,571,0002.25%
Quantum Private Wealth, LLC 73,772$4,514,0001.95%
View complete list of INTRA CELLULAR THERAPIES INC shareholders